Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director · PRESIDENT & CEO | September 30, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date September 30, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 49,923 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Purchase · Acquired 30,000 · Balance 49,923 |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 14,300 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,300 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 1, 2026 17:19 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Shares | 30,000 | $37.38 | $1,121,400.00 |
DisclosureSEC source: 0001193125-26-409999 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,923 Read SEC document |
| March 13, 2026 Filed Mar 14, 2026 00:16 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 7,308 | $55.23 | $403,584.30 |
DisclosureSEC source: 0001193125-26-106724 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,923 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:16 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionRestricted Share Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-106724 · ownership.xml · derivative · entry 4 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F1 · derivative.exercise_date: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F1 · derivative.expiration_date: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:16 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-106724 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F1 · price: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 11,269 | $60.11 | $677,357.05 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 15 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,731 F12 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionPerformance Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · derivative · entry 22 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F11 · derivative.exercise_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F11 · derivative.expiration_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantPerformance Share Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · derivative · entry 21 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F11 · derivative.exercise_price: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F11 · shares: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F11 · derivative.exercise_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F11 · derivative.expiration_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option · Derivative | 65,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · derivative · entry 20 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 65,000 shares Expires 2029-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option · Derivative | 105,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · derivative · entry 19 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 105,000 shares Expires 2028-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · derivative · entry 18 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2027-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option · Derivative | 75,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · derivative · entry 17 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 75,000 shares Expires 2027-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 14 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · shares: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F11 · price: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 65,000 | $62.06 | $4,033,900.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 13 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 65,000 | $9.44 | $613,600.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 12 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 61,652 | $60.08 | $3,704,052.16 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 11 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.75 to $60.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 43,348 | $59.26 | $2,568,802.48 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 10 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,652 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.745 to $59.735, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 105,000 | $4.75 | $498,750.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 9 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,449 | $61.26 | $150,025.74 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 8 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $61.055 to $61.555, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 10,072 | $60.47 | $609,053.84 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 7 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.05 to $61.035, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 12,479 | $59.50 | $742,500.50 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 6 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,521 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.03 to $60.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 25,000 | $3.10 | $77,500.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 5 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 21,515 | $60.49 | $1,301,442.35 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 4 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.16 to $61.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 31,694 | $59.88 | $1,897,836.72 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 3 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,515 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.16 to $60.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 21,791 | $58.81 | $1,281,528.71 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,209 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.16 to $59.1425, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 75,000 | $8.40 | $630,000.00 |
DisclosureSEC source: 0001193125-26-102666 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 23:51 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-009230 · ownership.xml · derivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 23:51 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0001193125-26-009230 · ownership.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Shares · 350,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:49 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0001193125-26-001172 · ownership.xml · derivative · entry 5 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:49 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,062 | $44.93 | $92,645.66 |
DisclosureSEC source: 0001193125-26-001172 · ownership.xml · nonDerivative · entry 3 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $44.91 to $45.125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:49 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 37,938 | $44.40 | $1,684,447.20 |
DisclosureSEC source: 0001193125-26-001172 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,062 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $43.91 to $44.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:49 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 40,000 | $7.49 | $299,600.00 |
DisclosureSEC source: 0001193125-26-001172 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 00:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,010 | $46.32 | $93,103.20 |
DisclosureSEC source: 0001193125-25-313147 · ownership.xml · nonDerivative · entry 3 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.02 to $46.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 00:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 8,820 | $45.59 | $402,103.80 |
DisclosureSEC source: 0001193125-25-313147 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,010 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $45.02 to $46.013, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 05, 2025 Filed Dec 10, 2025 00:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 14,375 | $45.03 | $647,306.25 |
DisclosureSEC source: 0001193125-25-313147 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,830 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $45.00 to $45.135, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 28, 2025 Filed Dec 4, 2025 01:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 97 | $45.01 | $4,365.97 |
DisclosureSEC source: 0001193125-25-307211 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,205 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 23:17 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.69 | $0.00 |
DisclosureSEC source: 0001193125-25-227202 · ownership.xml · derivative · entry 4 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT, CEO & INTERIM CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 23:17 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 25,000 | $40.16 | $1,004,000.00 |
DisclosureSEC source: 0001193125-25-227202 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT, CEO & INTERIM CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.495, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 23:17 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 25,000 | $7.69 | $192,250.00 |
DisclosureSEC source: 0001193125-25-227202 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT, CEO & INTERIM CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 23:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039025 · ownership.xml · derivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 23:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $35.48 | $0.00 |
DisclosureSEC source: 0000950170-25-039025 · ownership.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Shares · 275,000 shares Expires 2035-03-11 F1 · derivative.exercise_date: Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,315 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · derivative · entry 12 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,315 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,149 | $41.07 | $47,189.43 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 8 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $41.01 to $41.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 1,149 | $17.76 | $20,406.24 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 7 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 15,166 | $40.46 | $613,616.36 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 6 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 27, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 15,166 | $17.76 | $269,348.16 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 5 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,468 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · derivative · entry 11 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,315 Underlying: Common Shares · 22,468 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 22,468 | $40.20 | $903,213.60 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 4 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.535, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 22,468 | $17.76 | $399,031.68 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 3 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,217 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · derivative · entry 10 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,783 Underlying: Common Shares · 16,217 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 16,217 | $40.08 | $649,977.36 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.